CIC and Babraham Bioscience Technologies are among the co-founders of Start Codon, a life sciences accelerator set to invest in up to 50 seed-stage startups over the next five years.
Cambridge Innovation Capital (CIC), the patient capital fund established by University of Cambridge, yesterday joined a group of investors including Genentech, the biotech subsidiary of pharmaceutical firm Roche, to co-found healthcare and life sciences accelerator Start Cordon.
The co-founders also include Babraham Bioscience Technologies, which manages the bioscience-focused Babraham Research Campus, as well as Jonathan Milner, a member of CIC’s advisory panel and founder of research antibody provider Abcam, and Ian Tomlinson, chairman of commercialisation fund Apollo Therapeutics.
